Although recent clinical successes with immunotherapies demonstrate their potential 1,2 , in most cases it remains difficult to generate sufficiently robust immune responses to achieve lasting therapeutic success. Biomaterials may be useful to enhance the effectiveness of vaccines and other immunotherapies [3] [4] [5] [6] [7] [8] . The design and fabrication of porous materials have been intensively investigated to pursue new material properties for a variety of applications including cell and tissue engineering and regenerative medicine [9] [10] [11] . Recently, it has been proposed that in vivo modulation of host cell populations can be achieved using three-dimensional (3D) biomaterials with spatiotemporal control of biochemical and mechanical cues 3,12-14 . However, 3D biomaterials are typically fabricated in vitro, requiring surgical placement in the body, and their preformed structures could limit the capability of host cells to organize themselves.
A r t i c l e s
Although recent clinical successes with immunotherapies demonstrate their potential 1, 2 , in most cases it remains difficult to generate sufficiently robust immune responses to achieve lasting therapeutic success. Biomaterials may be useful to enhance the effectiveness of vaccines and other immunotherapies [3] [4] [5] [6] [7] [8] . The design and fabrication of porous materials have been intensively investigated to pursue new material properties for a variety of applications including cell and tissue engineering and regenerative medicine [9] [10] [11] . Recently, it has been proposed that in vivo modulation of host cell populations can be achieved using three-dimensional (3D) biomaterials with spatiotemporal control of biochemical and mechanical cues 3, [12] [13] [14] . However, 3D biomaterials are typically fabricated in vitro, requiring surgical placement in the body, and their preformed structures could limit the capability of host cells to organize themselves.
Here we propose an approach in which host immune cells are recruited and modulated in vivo by 3D scaffolds that spontaneously assemble from mesoporous silica rods (MSRs) of high aspect ratio (Fig. 1) . Owing to their high pore volume and large surface area, mesoporous silica has been intensively investigated for controlled drug release [15] [16] [17] . In general, synthetic amorphous silica is known to have good biocompatibility 18, 19 , supporting its development as a versatile platform for clinical applications. In this study, we describe injectable pore-forming scaffolds based on MSRs, and demonstrate their application to in vivo modulation of host immune cells and potential as a vaccine platform to provoke adaptive immune responses.
RESULTS

Injected MSRs spontaneously form a 3D microenvironment
We first hypothesized that rod-shaped mesoporous silica particles with high aspect ratio could nonspecifically assemble, or coalesce to form structures with significant interparticle spaces (pores) upon subcutaneous injection in vivo. If interparticle pores generated by particle assembly are bigger than the size of cells, host cells could potentially infiltrate into that space. To test this idea, we synthesized MSRs with a hexagonal mesoporous structure through the silica sol-gel reaction in the presence of a pore-directing agent, Pluronic block copolymer P123 (refs. 20,21) . The MSRs were, on average, 88 µm in length and 4.5 µm in diameter, as measured by scanning electron microscopy (SEM) (Fig. 2a) , and had cylindrical mesopores as measured by transmission electron microscopy (TEM) (Fig. 2a) . The N 2 adsorption/desorption isotherms were type IV isotherms with a hysteresis loop 20 , demonstrating the mesoporous characteristic of the MSR ( Supplementary  Fig. 1a ) with a 10.9-nm pore size (Supplementary Fig. 1b) . The Brunauer-Emmett-Teller (BET) surface area and the total pore volume were 703 m 2 g −1 and 1.33 cm 3 g −1 , respectively. SEM imaging of MSRs on a model substrate demonstrated random particle assembly, with interparticle spaces of tens of micrometers (Fig. 2a) . To test if the MSRs could be randomly assembled in vivo, MSRs dispersed in PBS were injected by needle into the dorsal flanks of mice. A large bump was formed immediately after injection owing to the volume of the buffer. The outward diffusion of the dispersion buffer occurred in less than 30 min and led to the disappearance of the initial bump. Implanting materials in the body to program host immune cells is a promising alternative to transplantation of cells manipulated ex vivo to direct an immune response, but doing so requires a surgical procedure. Here we demonstrate that high-aspect-ratio, mesoporous silica rods (MSRs) injected with a needle spontaneously assemble in vivo to form macroporous structures that provide a 3D cellular microenvironment for host immune cells. In mice, substantial numbers of dendritic cells are recruited to the pores between the scaffold rods. The recruitment of dendritic cells and their subsequent homing to lymph nodes can be modulated by sustained release of inflammatory signals and adjuvants from the scaffold. Moreover, injection of an MSR-based vaccine formulation enhances systemic helper T cells T H 1 and T H 2 serum antibody and cytotoxic T-cell levels compared to bolus controls. These findings suggest that injectable MSRs may serve as a multifunctional vaccine platform to modulate host immune cell function and provoke adaptive immune responses.
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At around 4 h, a small nodule began to form. The size of the nodule increased over time (Fig. 2b) and remained apparent for at least 2 weeks. To examine if the injected MSRs were assembled, MSRs conjugated covalently with rhodamine dye were injected, and the nodule was isolated after 24 h. Fluorescent microscopy revealed a random assembly of MSRs into 3D structures with interparticle spaces (Fig. 2c) , as observed with SEM in vitro (Fig. 2a) .
MSR scaffold is capable of recruiting host cells Next, the ability of host cells to infiltrate the interparticle pores of injected MSR scaffolds in vivo was examined. MSRs were again injected into the subcutaneous tissue of mice, and the nodule was retrieved at designated time points. The injection of MSRs did not induce a noticeable wound in the skin of the mice. The histology of nodules retrieved on day 3 demonstrated high cellular infiltration into the interparticle spaces and almost no collagen deposition or fibroblast infiltration (Fig. 2d) . Nodules retrieved at day 7 ( Fig. 2e) were analyzed with SEM, confirming they were composed of a high number of cells that completely occupied the structure ( Fig. 2f and Supplementary Fig. 2) . Removal of the cells, followed by SEM imaging revealed the underlying structure formed by the injected MSRs (Fig. 2g) . Over 90% of the isolated cells were viable (Fig. 2h) .
As interparticle pores formed through the spontaneous assembly of particles with elongated shapes, we hypothesized that longer MSRs with higher aspect ratio would lead to the formation of larger spaces than particles with lower aspect ratio, thus providing more room for cells to infiltrate. Higher (88 × 4.5 µm in length and diameter) and lower (37 × 3.2 µm in length and diameter, Supplementary Fig. 3 ) aspect-ratio MSRs were synthesized and injected subcutaneously, and the numbers of recruited cells were analyzed on day 7 after injection. As hypothesized, higher-aspect-ratio MSRs led to 2.5-fold more cells residing in the structures than lower-aspect-ratio MSRs (Fig. 2i) . Fifty-three million cells were recruited to structures formed from the high-aspect-ratio particles (20 mg). To determine whether the number of recruited cells is overestimated because of background cell counts, we extracted MSRs from mice that had been injected only 20 min earlier. There were 22 times fewer cells than found after 24 h, and 374 times fewer than after 5 d, indicating cells measured in the MSR scaffolds were recruited over time, and were not contaminating cells from the surrounding tissue. As an innate immune response is likely induced upon injection of MSRs, we analyzed whether CD11c + dendritic cells, important professional antigen-presenting cells that bridge innate and adaptive immunity, were present. MSR injection and assembly led to the recruitment of 15 million CD11c + dendritic cells to the high-aspect-ratio MSRs, which is a 2.5-fold increase as compared to structures from the lower-aspect-ratio particles (Fig. 2i) . These results indicate that simple, injectable MSRs provide a material platform for infiltration of large numbers of host immune cells. As the macroporous structure is spontaneously generated in vivo, this spontaneously assembling scaffold allows one to bypass ex vivo synthesis of the scaffold and to minimize geometric and spatial constraints of a preformed scaffold.
To determine the role of mesopores and macropores in recruiting cells, we compared cell recruitment using two control materials based on MSRs. One was pore-filled silica microrods with the same aspect ratio and morphology, but almost no mesoporosity compared to MSRs (Supplementary Fig. 4a-c) . The other control was monolithtype (pressed) MSRs maintaining the intrinsic mesopores of MSRs but lacking interparticle macropores ( Supplementary Fig. 4d,e) . The numbers of host cells recruited at day 3 into the same mass of both pore-filled silica microrods and pressed MSRs were significantly lower than those recruited into pristine MSRs (Fig. 2j) . This result clearly indicates that the interparticle macropores formed by MSR assembly are crucial to recruit a high number of cells. This result also indicates that a constant mass of MSRs is more effective than nonporous silica rods, likely because a higher number of MSR particles is present at constant mass due to their lower density, resulting in more interparticle macropores.
The biodegradability of biomaterials is an important issue in the body. It is known that mesoporous silica can degrade into silicic acid in vitro and in vivo over time [22] [23] [24] . To indirectly investigate in vivo degradation and clearance of the MSR scaffolds in the injection site, we measured the size of the subcutaneous nodule over time after injection of blank MSRs (Fig. 2k) . The nodule increased in size until day 7, and was reduced to an almost unmeasurable size after 25 d. Fluorescent imaging of sections of the nodule retrieved at day 7 after injection MSRs labeled with fluorescent protein showed the random assembly of MSRs surrounded by the recruited cells ( Fig. 2l and Supplementary Movie 1), whereas the sectioned nodule at day 28 showed very few MSRs (Fig. 2m and Supplementary Movie 2) . These results indicate that the injected MSRs were significantly degraded in vivo after subcutaneous injection. There was no significant toxicity or inflammation in liver, kidney or other organs of the mice injected with MSRs. We did not observe any difference in animal behavior after injection compared to naive animals. Animals appeared to tolerate the injections well and made no efforts to disturb the injection site, suggesting it did not present much discomfort or pain.
Sustained release of signaling molecules from MSR-scaffold We next examined whether small signaling molecules could be loaded into the pores of the MSRs and released from the particles in a sustained manner. First, incorporation of a cytokine, granulocytemacrophage colony-stimulating factor (GM-CSF), a potent stimulator of dendritic-cell recruitment and proliferation 25, 26 , was examined. The release of GM-CSF, measured with radioactive factor, showed a typical burst of release followed by a sustained release of 66% of the 
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A r t i c l e s total loaded GM-CSF by day 40 ( Supplementary Fig. 5 ), whereas the release measured by enzyme-linked immunosorbent assay (ELISA) shows nearly first-order release with a lower level of bioactive GM-CSF released (Fig. 3a) . The released GM-CSF resulted in in vitro bone marrow-derived dendritic cell (BMDC) proliferation, indicating the continuous release of bioactive GM-CSF for at least 35 d. We hypothesized that the recruitment of immature dendritic cells could be enhanced by GM-CSF release, and MSRs (5 mg) loaded with 0, 500, 1,000 or 3,000 ng of GM-CSF were injected into subcutaneous tissue and subsequently retrieved to analyze the dendritic cell population. CD11c + CD11b + , a widely accepted marker for conventional dendritic cells was used to determine dendritic cell numbers. In addition, the expression levels of a costimulatory surface marker, CD86, and major histocompatibility complex (MHC) II were used to assess dendritic cell activation 27, 28 . Dose-dependent increases in CD11c + CD11b + and CD11c + MHC II + dendritic cells were found in the scaffolds with GM-CSF release (Fig. 3b) . The numbers of total cells and dendritic cells were still higher in vaccine scaffolds than in the blank scaffold at day 14 ( Supplementary Fig. 6 ). Next, the ability of MSRs to provide cues to modulate the phenotype of dendritic cells was analyzed. To efficiently mature dendritic cells, danger signals containing conserved molecular patterns present in common infectious agents, termed pathogen-associated molecular patterns (PAMPs), are required to bind to pattern-recognition receptors such as Toll-like receptors (TLRs) 29 . The unmethylated cytosinephosphate-guanine oligonucleotide (CpG-ODN) sequence, a potent agonist for TLR9, was used in this study, as previous studies have shown that vaccines containing CpG-ODN can elicit strong CD8 killer T cell-mediated immune responses 30 . In vitro, a burst of CpG-ODN release was followed by a sustained release at a much lower rate (Fig. 3c) . To evaluate whether co-loading of CpG-ODN with GM-CSF could activate dendritic cells in vivo, we analyzed the expression of CD86 and MHC II in dendritic cells retrieved from MSR releasing solely GM-CSF (MSR-GM) and from MSR releasing both GM-CSF The cryosections were stained with DAPI and rhodamine-phalloidin. Biological replicates were used, and studies were repeated at least two times in the laboratory. Error bars, mean ± s.d. *P < 0.05.
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and CpG-ODN (MSR-GM-CpG) at day 3 after injection. MSR-GMCpG yielded 1.3-and 2.5-fold increases in the number of recruited dendritic cells expressing CD86 + and MHC II + , as compared to MSR-GM ( Fig. 3d and Supplementary Fig. 7 ). As the level of endotoxin in the MSRs was below the detection limit of the endotoxin assay, the activation of dendritic cells was not derived from undesired contamination of MSRs. We next verified that MSRs can be loaded with protein antigens, and they present the antigens in a sustained manner. In vitro, OVA was released relatively quickly, with ~45% released within 5 d (Supplementary Fig. 8 ). To investigate in vivo release of OVA from MSRs, MSRs were loaded with Alexa Fluor 647-labeled OVA (MSR-OVA*); the duration of MSR-OVA* at the vaccine site was compared to the duration of an injection of bolus OVA* only, using near-infrared fluorescent imaging (Fig. 3e) . The fluorescence at the site of bolus OVA* injection decreased to 10% of the initial level by day 1 after injection, whereas the MSR-OVA* maintained 60% of the initial OVA* level. At day 10 after injection, the OVA* remaining at the vaccination site was still 10.6-fold higher in MSR-OVA* than in the bolus OVA* condition, suggesting that MSRs are a good candidate for sustained release of antigenic proteins in microenvironments housing antigenpresenting cells.
MSR vaccine modulates dendritic cells to exert systemic effects MSR-based scaffolds (5 mg MSRs) containing OVA, GM-CSF and CpG-ODN were then examined for their ability to function as vaccines. Cell recruitment to vaccine scaffolds, compared with blank MSR scaffolds, at different time points was analyzed first. The total number of cells recruited to both systems increased over time, but the vaccine MSR scaffold held 1.8-and 6.5-fold more cells at days 5 and 7, respectively, than the blank MSR scaffold (Fig. 4a) . Further analysis of the cell composition revealed that the recruited cells in the MSR vaccine consisted mainly of CD11c + dendritic cells (10%), B220 + B cells (21%) and CD14 + monocytes (52%) (Supplementary  Fig. 9 ). CD11c + dendritic cells increased over time, and ~4-to 6-fold higher numbers were observed than in blank MSR scaffolds (Fig. 4b) . The level of GM-CSF in the tissue between 1 mm and 3 mm from the injection site was also analyzed, to confirm GM-CSF release in vivo (Fig. 4c) . Higher GM-CSF levels were maintained for over a week at MSR vaccine sites, compared to sites receiving blank MSR particles.
The ability of assembled MSRs to allow recruited dendritic cells to process antigen, subsequently traffic to the draining lymph nodes (dLN), and to interact with other immune cells, was then analyzed. Mice were initially immunized with MSR containing only OVA* or both OVA* and GM-CSF. Seven days after injection, the cells in dLN were extracted and analyzed. Delivery of the antigen alone in the MSR scaffold resulted in a slight increase in the number of AF647 + CD11c + dendritic cells in the dLN, whereas with the addition of GM-CSF, the number was drastically increased (Fig. 4d) . Including CpG with the GM-CSF and OVA* in the MSR scaffold further increased the number of CD11c + CD86 + -activated dendritic cells in the dLN, compared to MSR releasing only GM-CSF and antigen (Fig. 4e) . To test the ability of recruited dendritic cells to process antigen at the site of vaccination and traffic antigen to the dLN, we loaded MSRs with 300 µg of OVA and analyzed the dLN for the presence of dendritic cells presenting OVA257-264 peptide (SIINFEKL) on the major histocompatibility complex I (MHC I) 7 days after injection. The MSR vaccine was capable of generating a significant number (P < 0.05) of SIINFEKL-MHC I + CD11c + dendritic cells in the dLN (Fig. 4f and  Supplementary Fig. 10) .
To test the ability of the MSR-primed dendritic cells to interact with other immune cells in the dLN, we again immunized mice, harvested the dLNs and analyzed them for formation of a germinal center where immature B cells with antigenic information undergo affinity maturation and somatic hypermutation to generate specific antibody-producing plasma B cells 31 . MSR with OVA alone, and the full MSR vaccine both elicited strong germinal center formation, in an OVA dose-dependent manner ( Fig. 4g and Supplementary Fig. 11) , indicating that the antigenpresenting dendritic cells exert downstream effects on the B cells in the dLN. Taken together, these data suggest that the MSR vaccine is able to recruit dendritic cells, program them with a danger signal while loading them with antigen, and enhance their trafficking to the dLN to present processed antigen to other immune cells. 
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MSR vaccine generates potent adaptive immune responses
Finally, the ability of the MSR vaccine to induce antigen-specific adaptive immune responses was studied. A single immunization with MSRs loaded with OVA, GM-CSF and CpG elicited strong and durable titers of sera anti-OVA IgG 2a (Fig. 5a ) and IgG 1 (Fig. 5b) , indicative of T H 1 and T H 2 responses, respectively. Notably, immunization with MSRs loaded with only OVA elicited a strong antibody response as well, but the response was primarily skewed toward a T H 2 response. By contrast, vaccination with equivalent amounts of GM-CSF, CpG-ODN and OVA as delivered by the MSR, but in bolus form instead, elicited only a moderate and T H 1-skewed response that soon decreased after 100 d. Vaccination with bolus OVA alone led to minimal antibody generation, as expected. To further characterize the T H 1 and T H 2 responses elicited by MSRs loaded with OVA (MSR + OVA) and the MSR vaccine, we analyzed the production of interferon (IFN)-γ, a key T H 1 cytokine, and interleukin (IL)-4, a key T H 2 cytokine, after co-culture of the spleen CD4 + T cells (isolated at day 10 after vaccination) with OVA323-339 peptidepulsed BMDCs (Supplementary Fig. 12 ). MSR + OVA and the full MSR vaccine showed equally high production of IFN-γ, indicating that the MSR scaffold is capable of driving a strong immune-stimulatory response against OVA. However, the MSR + OVA condition resulted in significantly higher (P < 0.05) IL-4 production as compared to the MSR vaccine. Taken together, CD4 + T cells primed by the MSR + OVA had a lower IFN-γ to IL-4 ratio, which could explain the observation that the MSR vaccine leads to high levels of both IgG 2a and IgG 1 serum antibodies, whereas the MSR + OVA formulation was able to elicit only a strong IgG 1 serum antibody.
To compare the MSR vaccine with a conventional adjuvant vaccine using a prime followed by boost strategy, we vaccinated animals with bolus OVA, bolus vaccine formulation (GM-CSF + CpG + OVA), Imject Alum with OVA, MSR with OVA, and the MSR vaccine formulation on day 0, and boosted those with the same formulations on day 30. We collected serum biweekly or weekly and measured serum IgG 2a (Fig. 5c) and IgG 1 (Fig. 5d) antibody against OVA. MSR vaccine resulted in the highest IgG 1 and IgG 2a titers as compared with all other groups after primary vaccination. Boosting further increased antibody production in all conditions. Boosting increased the anti-OVA IgG 2a level resulting from the bolus vaccine formulation to a similar level as that induced by the first injection of the MSR vaccine (Fig. 5d) . This suggests that the MSR vaccine is a potent platform to induce high serum antibody titers and has potential as a single-shot vaccine technology.
Strong humoral responses are highly dependent on the action of CD4 + T follicular helper (T FH ) cells 32 . Therefore, we investigated whether the MSR vaccine induced the differentiation of antigenspecific T FH cells. After mice were vaccinated with MSRs containing OVA, MSRs containing lysozyme as a negative control, and the full MSR vaccine, 5-(6)-carboxyfluorescein diacetate succinimidyl ester (CFSE)-stained Thy1.2 + splenocytes from OT-II mice were adoptively transferred into Thy 1.1 + C57Bl/6 mice. The CD4 + T cells in OT-II mice have T-cell receptors that specifically recognize a sequence on the OVA protein. Four days after the mice were immunized, their dLN and spleens were harvested, and the transferred Thy 1.2 + cells were analyzed. Mice immunized with the full MSR vaccine or MSR loaded with OVA showed significant proliferation of Thy1.2 + CD4 + T cells (Fig. 5e) , and generated a significant (P < 0.05) CD4 + CXCR5 + T helper cell clonal expansion (Fig. 5f) and T FH differentiation, whereas mice vaccinated with lysozyme as antigen did not. Together, these data suggest the MSRs have the ability to incorporate and release a variety of factors to induce both T H 1 and T H 2 responses. Figure 5j , which is expressed as mean ± s.e.m. *P < 0.05; **P < 0.01; ***P < 0.001.
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A r t i c l e s T cells (Fig. 5g and Supplementary Fig. 13 ) and IFN-γ secreting CD8 + T cells (Fig. 5h) were found in the spleens of vaccinated mice. To evaluate antigen-specific CD8 + T-cell expansion in vivo, we adoptively transferred CFSE-stained splenocytes isolated from OT-I transgenic mouse into naive mice and mice immunized with the MSR-vaccine. CD8 + CTL T cells in OT-I mice have a transgenic T-cell receptor designed to recognize SIINFEKL-MHC I complex expressed on antigen-presenting cells. Seven days after adoptive transfer of CFSE-stained OT-I T cells, the cells in dLNs and spleen were retrieved from the recipient mice and CFSE fluorescence was analyzed by flow cytometry. The intensity of the CFSE fluorescence was measured as an indicator of T-cell proliferation, revealing that OT-I T cells proliferated substantially both in dLNs and spleens of vaccinated mice (Fig. 5i) . These data indicate immunization with the MSR-vaccine induces antigen-specific cellular responses that result in T-cell proliferation in response to the antigenic information.
To demonstrate one possible application of this approach, we investigated its effect in generating prophylactic tumor protection. Mice were immunized with MSR vaccines or controls and subsequently challenged with a subcutaneous injection of EG7.OVA lymphoma cells. MSR vaccines containing CpG-ODN, GM-CSF and OVA were found to delay the onset of tumor growth compared to bolus delivery of the same immune stimulatory agents, a mimic of conventional vaccination (Fig. 5j) . MSRs containing OVA (MSR + OVA) suppressed tumor growth in the early stage, but differences over the control condition were lost with time. A bolus vaccine (GM + CpG + OVA, 150 µg) resulted in tumor initiation at a similar time point (day 7) as naive mice, but delayed tumor growth significantly (P < 0.05). Tumor growth was much more delayed upon injection of MSR vaccines loaded with 50 µg or 150 µg of OVA. Tumor growth was first observed on day 21, and tumor volume was considerably less than the other conditions at all time points. The corresponding survival rate also supports the potential utility of the current MSR strategy for prophylactic cancer vaccines (Fig. 5k) .
DISCUSSION
This study demonstrates that MSRs are capable of forming, in situ, macroporous structures that provide a 3D microenvironment for housing and modulating large numbers of immune cells in vivo. Although there has been past work to assemble DNA, peptides and nanoparticles, the resulting structures were limited to nanostructures for drug delivery or microstructures for in vitro cell culture 33 . In this study the interparticle macropores formed by mesoporous silica microparticles could hold host cells. This approach eliminates the need for ex vivo construction of a predefined 3D scaffold and brings the assembly process in vivo. Although the current microparticles create random pore structures, designing molecular interactions between microparticles could allow self-assembly into a predesigned, macroporous structure in vivo. In addition to cell recruitment, the structure of the MSRs could alter various aspects of cellular phenotype, including cytoskeletal architecture, and differentiation and proliferation 34 .
The number of cells within MSR scaffolds is substantially higher than the number previously reported to be recruited to preformed macroporous polymer scaffolds 3, 4 . Generating interparticle macropores using high-aspect-ratio MSRs appears to be crucial to cell number, and the ability of resident cells to reorganize the particles may generate space for additional cell infiltration. The innate immune response to silica likely also contributed to the infiltration of high numbers of host immune cells. Particulates such as silica crystal 35 , crystals of monosodium urate (MSU) 36 and aluminum hydroxide (alum) 37 have inflammatory properties, as they are sensed by the cytoplasmic receptor NALP3. Amorphous silica nanoparticles have recently been shown to activate the NALP3 inflammasome as well 38 . Although MSRs used in this system are larger than cells and are unlikely to be internalized intact, it is possible that smaller particles are produced during their degradation in vivo over time and internalized by cells, resulting in NALP3 activation. Surface hydroxyl groups have also been linked to alternative complement activation 39 . We speculate that NALP3 activation and complement binding are likely involved in inflammation resulting from MSRs.
To modulate the recruited host immune cells, we exploited the high surface area and pore volume of the MSRs to achieve sustained release of a small inflammatory molecule (GM-CSF), a single-stranded DNA (ssDNA) TLR agonist (CpG-ODN) and a model antigen protein (OVA). This approach prolongs presentation of these molecules in the surrounding tissue, allowing one to modulate dendritic cell enrichment, activation and antigen processing, and subsequent homing to lymph nodes. The current release profile is based on diffusion of loaded molecules from the mesopores, but the release rate could be further actively controlled 40, 41 .
We observe substantial enrichment of myeloid dendritic cells in GM-CSF-releasing scaffolds, which is likely a combined effect of peripheral dendritic cell migration and in situ differentiation of dendritic cells from precursors. Prolonged presentation of antigens and adjuvants to immune cells, which is believed to be crucial to enable long-term stimulation of dendritic cells in order to break immune tolerance 42, 43 , has been demonstrated to yield potent immune responses in past studies 7, 44 . MSRs loaded with OVA, GM-CSF and CpG-ODN were here found to enhance systemic IgG 2a and IgG 1 serum antibody levels and CTL responses, compared to bolus vaccine formulations. The induction of these strong humoral and cellular immune responses is likely a result of the high number of dendritic cells, their sustained and prolonged activation and priming, and their subsequent interactions with CD4 and CD8 T cells in the lymph node.
The ability to tune the immune response is one of the advantages of the MSR system. In this study, CpG was used to activate the dendritic cells to secrete T H 1 cytokines and prime CD8 + and CD4 + T cells. The boost of the IgG 2a antibody response and anti-tumor effect with the MSR vaccine are likely the manifestation of a T H 1 response. Sustained delivery of antigens and adjuvants from the MSRs probably contributes to, though is not solely responsible for, generating high serum antibody titers. Previous work using polymer nano-or microparticles to release antigens and adjuvants 45, 46 led to moderate antibody titers, and a stronger antibody titer required a secondary boost. In contrast, with MSRs, a single prime injection was sufficient to induce antibody titers over two orders of magnitude higher than that of the bolus control, and comparable to a prime boost using bolus vaccination. Although Alum loaded with OVA and CpG induces high IgG 1 serum antibody titer, it induces lower IgG 2a serum titer than bolus formulations composed of OVA and CpG, suggesting it is not effective at inducing a T H 1-skewed immune response 47 . In contrast, the MSR vaccine leads to high levels of both IgG 2a and IgG 1 serum antibodies. These results indicate that cell enrichment along with sustained release of antigens and adjuvants plays a key role in driving the potent immune response. The immunoactive nodule generated by the MSR system can likely generate cell-cell and cellmaterial interactions that are crucial to the development of potent CTL and antibody responses.
This injectable scaffold may provide a useful platform for prophylactic and therapeutic vaccination. The success of the human papillomavirus vaccine in cervical cancer has created interest in additional npg A r t i c l e s prophylactic opportunities for other types of cancer where individuals at high risk (e.g., breast cancer) can be identified in advance, and tumor antigens common to many patients or patient-specific antigens are being actively identified. The prophylactic tumor vaccine study using MSRs clearly demonstrates that this injectable scaffold system has potential to suppress the growth of tumors. However, the major value of this new technology would likely be as a therapeutic cancer vaccine, and additional studies are required to test its activity in that setting. In addition, the striking serum antibody response induced by this approach is likely relevant to the treatment of viral diseases that are resistant to conventional treatment. The injection site reactions may not be acceptable in situations where the disease does not present a significant danger to the patient. However, in diseases that are both life threatening and resistant to conventional therapy, we do not believe an injection site reaction would be a significant impediment to vaccine use.
The biodegradation and safety of the injected MSRs should be considered for potential medical applications. Mesoporous silica is composed of an amorphous silica, which degrades in the body over time 23, 24 . Synthetic amorphous silica is generally recognized as safe by the US Food and Drug Administration, and is used in cosmetics and as a food additive. The current administration route (subcutaneous injection) and quantity (5 mg) of MSR used in these studies resulted in a substantial biodegradation in 28 d and did not cause severe local inflammation, side effects or animal mortality, indicative of the biocompatibility of this technology. This is obviously in contrast with another type of fibrous silica, asbestos, which is a crystalline material that does not degrade in the body, and thus acts as a carcinogen. We plan to investigate the in vivo degradation of MSRs and associated duration of inflammation in more depth in the future.
Looking forward, the physicochemical properties of MSRs could be further tuned, including the coupling of surface ligands, to enhance their capability to modulate cell behavior. This system could be further applied to other fields, possibly including detection of circulating tumor cells or recruitment of stem cells.
METHODS
Methods and any associated references are available in the online version of the paper. 
